Gilead Sciences HIV Prevention Treatment Shows 100% Effectiveness in Phase 3 Trial
By Dean Seal
Gilead Sciences said an interim analysis of its lenacapavir study showed 100% efficacy in HIV prevention in cisgender women, resulting in a recommendation that the treatment be opened to all trial participants.
The biopharmaceutical company said the phase 3 trial of its twice-yearly injectable HIV-1 capsid inhibitor met key efficacy endpoints of showing superiority to once-daily oral Truvada and background HIV incidence.
The independent data monitoring committee has recommended that Gilead stop the blinded phase of the trial and offer open-label lenacapavir to all participants.
Gilead said this is the first phase 3 HIV prevention trial to show zero infections.
The company expects results from the lenacapavir program's other phase 3 trial in late 2024 or early 2025. That trial assesses the treatment for pre-exposure prophylaxis, or PrEP, in cisgender men who have sex with men, transgender men, transgender women and gender non-binary individuals who have sex with partners assigned male at birth.
Gilead said the regulatory filing for lenacapavir for PrEP will include the results of both Phase 3 trials.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
June 20, 2024 09:51 ET (13:51 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now